stockrowLENSAR, Inc.
LNSR Healthcare Medical Devices
LENSAR, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $58.4 million, up 9.24% from fiscal 2024.
- Revenue
- +18.4%
- EPS
- +291.7%
- Free cash flow
- +96.8%
Quarter to June 2026, against a year earlier
Follow LNSR
Alert me
LENSAR, Inc. (LNSR) EV/Sales
As of 5 November 2026, LENSAR, Inc. (LNSR) trades at a EV/Sales of 1.0×. Over the past ten years it has ranged from −0.2× (January 2021) to 3.3× (March 2025); the current reading is higher than 41% of that period. That is below the Medical Devices industry median of 2.7× and below the Healthcare sector median of 3.5×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 2.2× | 34.32% |
| FY2024 | 1.6× | 157.50% |
| FY2023 | 0.6× | 15.02% |
| FY2022 | 0.5× | (38.75%) |
| FY2021 | 0.9× | — |
| FY2020 | 0.0× | — |
| FY2019 | 1.2× | 0.00% |
| FY2018 | 1.2× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 1.0× | (7.67%) |
| Mar 2026 | 1.1× | (48.10%) |
| Dec 2025 | 2.2× | (6.69%) |
| Sep 2025 | 2.3× | (4.78%) |
| 24 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| NYXH Nyxoah SA compare | 0.1× |
| OM Outset Medical, Inc. compare | 0.3× |
| LNSR LENSAR, Inc. | 1.0× |
| ECOR electroCore, Inc. compare | 2.1× |
| HYPR Hyperfine, Inc. compare | 2.3× |
| LUCD Lucid Diagnostics Inc. compare | 11.3× |
| MBOT Microbot Medical Inc. compare | 15.0× |
| COCH Envoy Medical, Inc. compare | 389× |
| SERA Sera Prognostics, Inc. compare | 641× |
| Medical Devices industry median | 2.7× |
| Healthcare sector median | 3.5× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)